Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta‐analysis

To assess the efficacy and safety of liraglutide to reduce visceral and ectopic fat in adults with or without type 2 diabetes mellitus (T2DM).

[1]  K. Cusi,et al.  Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. , 2022, The lancet. Diabetes & endocrinology.

[2]  Xiu-Fang Lv,et al.  Effect of glucagon‐like peptide‐1 receptor agonists on fat distribution in patients with type 2 diabetes: A systematic review and meta‐analysis , 2022, Journal of diabetes investigation.

[3]  Shuangqing Li,et al.  Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis , 2021, Frontiers in Endocrinology.

[4]  M. Li,et al.  [The effects of liraglutide on body composition and muscle strength in adult obese patients with type 2 diabetes mellitus]. , 2021, Zhonghua nei ke za zhi.

[5]  P. Joshi,et al.  Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. , 2021, The lancet. Diabetes & endocrinology.

[6]  J. Rosenstock,et al.  Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. , 2021, The New England journal of medicine.

[7]  J. Holst,et al.  Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. , 2021, The New England journal of medicine.

[8]  Xiangjin Xu,et al.  Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial. , 2020, Diabetes research and clinical practice.

[9]  G. Iacobellis,et al.  Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity , 2020, Journal of the Endocrine Society.

[10]  Maurice B. Bizino,et al.  Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation , 2019, Diabetologia.

[11]  V. Welch,et al.  Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. , 2019, The Cochrane database of systematic reviews.

[12]  F. Hu,et al.  Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. , 2019, The lancet. Diabetes & endocrinology.

[13]  T. Vilsbøll,et al.  Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2019, The New England journal of medicine.

[14]  Maurice B. Bizino,et al.  A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients , 2019, Cardiovascular Diabetology.

[15]  G. Qin,et al.  Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease , 2019, Hepatology.

[16]  N. Lundbom,et al.  Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single‐centre randomized controlled study , 2018, Diabetes, obesity & metabolism.

[17]  A. Janež,et al.  Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. , 2018, European journal of endocrinology.

[18]  J. Holst,et al.  Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial , 2018, Diabetes, obesity & metabolism.

[19]  Tiejun Tong,et al.  Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range , 2015, Statistical methods in medical research.

[20]  F. Santilli,et al.  Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes , 2017, Diabetes Care.

[21]  J. Holst,et al.  Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial , 2017, JAMA psychiatry.

[22]  T. Yoshimoto,et al.  Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. , 2017, Endocrine journal.

[23]  K. Kos,et al.  GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction. , 2017, Clinical science.

[24]  M. Mohseni,et al.  Liraglutide causes large and rapid epicardial fat reduction , 2017, Obesity.

[25]  I. D. de Boer.  Liraglutide and Renal Outcomes in Type 2 Diabetes. , 2017, The New England journal of medicine.

[26]  D. Thijssen,et al.  A systematic review and meta‐analysis on the effects of exercise training versus hypocaloric diet: distinct effects on body weight and visceral adipose tissue , 2016, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[27]  Laurentiu M. Pop,et al.  Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin. , 2016, The Journal of clinical endocrinology and metabolism.

[28]  F. Porzsolt,et al.  Using machine learning to predict laboratory test results , 2016, Annals of clinical biochemistry.

[29]  Jiming Liu,et al.  Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range , 2014, BMC Medical Research Methodology.

[30]  Hiroki Sato,et al.  Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus. , 2013, Internal medicine.

[31]  K. Walsh,et al.  Adipokines in inflammation and metabolic disease , 2011, Nature Reviews Immunology.

[32]  D. Matthews,et al.  Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue , 2009, Diabetes, obesity & metabolism.

[33]  A. Astrup,et al.  Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2009, The Lancet.

[34]  G. Cowin,et al.  Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. , 2009, Journal of hepatology.

[35]  M. Prokop,et al.  Quantification of epicardial and peri-coronary fat using cardiac computed tomography; reproducibility and relation with obesity and metabolic syndrome in patients suspected of coronary artery disease. , 2008, Atherosclerosis.

[36]  M. Nagai,et al.  Development of a new method for estimating visceral fat area with multi-frequency bioelectrical impedance. , 2008, The Tohoku journal of experimental medicine.

[37]  S. R. Ferreira,et al.  Methods of estimation of visceral fat: advantages of ultrasonography. , 2003, Obesity research.

[38]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[39]  M D Jensen,et al.  Measurement of abdominal and visceral fat with computed tomography and dual-energy x-ray absorptiometry. , 1995, The American journal of clinical nutrition.

[40]  N Karstaedt,et al.  Adipose tissue determinations in cadavers--a comparison between cross-sectional planimetry and computed tomography. , 1990, International journal of obesity.

[41]  J. Seidell,et al.  Imaging techniques for measuring adipose-tissue distribution--a comparison between computed tomography and 1.5-T magnetic resonance. , 1990, The American journal of clinical nutrition.